Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02701400 · ClinicalTrials.gov registry record · Phase 2
Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer
A Phase 2 study of Recurrent Small Cell Lung Carcinoma, sponsored by Emory University.
- Completed
- Registry status
- Phase 2
- Development phase
- 18
- Enrollment target
- 2
- Study locations
NCT02701400 is a Phase 2 study of Recurrent Small Cell Lung Carcinoma that has completed, run by Emory University. The registered enrollment target is 18 participants. The trial reports 2 study locations across 1 state.
The verdict
NCT02701400, a Phase 2 study of Recurrent Small Cell Lung Carcinoma, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 18 participants
- Enrollment target
- 2
- Study locations
Study Summary
This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of tumor cells to grow and spread by enhancing immune function. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Giving tremelimumab and durvalumab together with radiation therapy may lead to improved clinical benefit.
Conditions Studied
Interventions
- BIOLOGICAL Durvalumab
- RADIATION Stereotactic Body Radiation Therapy
- RADIATION Hypofractionated Radiation Therapy
- BIOLOGICAL Tremelimumab
Study Locations (2)
Georgia
- Emory University Hospital Midtown - Atlanta
- Emory University/Winship Cancer Institute - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2016-04-14 |
| Est. Completion | 2020-08-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02701400
The ClinicalTrials.gov registry entry for NCT02701400 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Recurrent Small Cell Lung Carcinoma appearing as the primary indexed condition, and to 4 interventions - of which Durvalumab is the first listed.
NCT02701400 reports 2 study locations spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02701400 about?
NCT02701400 is a clinical study titled "Tremelimumab and Durvalumab With or Without Radiation Therapy in Patients With Relapsed Small Cell Lung Cancer". This randomized clinical trial studies how well tremelimumab and durvalumab with or without radiation therapy works in treating patients with small cell lung cancer that has returned after a period of improvement. Monoclonal antibodies, such as tremelimumab and durvalumab, may limit the ability of t...
What is the current status of trial NCT02701400?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 18 participants. The study started on 2016-04-14. Estimated completion is 2020-08-07.
What conditions does trial NCT02701400 study?
This clinical trial studies the following conditions: Recurrent Small Cell Lung Carcinoma.
What interventions are being tested in trial NCT02701400?
The interventions under investigation include: Durvalumab (BIOLOGICAL), Stereotactic Body Radiation Therapy (RADIATION), Hypofractionated Radiation Therapy (RADIATION), Tremelimumab (BIOLOGICAL).
Who is sponsoring clinical trial NCT02701400?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02701400 being conducted?
This trial has 2 study locations across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Small Cell Lung Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.